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Abstract
Objectives. To characterize the 10 year relationship between anti-transcriptional intermediary factor 1 antibody (anti-
TIF1-Ab) positivity and cancer onset in a large UK-based adult DM cohort.
Methods. Data from anti-TIF1-Ab-positive/-negative adults with verified diagnoses of DM from the UK Myositis
Network register were analysed. Each patient was followed up until they developed cancer. KaplanMeier methods
and Cox proportional hazard modelling were employed to estimate the cumulative cancer incidence.
Results. Data from 263 DM cases were analysed, with a total of 3252 person-years and a median 11 years of follow-up;
55 (21%) DM cases were anti-TIF1-Ab positive. After 10 years of follow-up, a higher proportion of anti-TIF1-Ab-positive
cases developed cancer compared with anti-TIF1-Ab-negative cases: 38% vs 15% [hazard ratio 3.4 (95% CI 2.2, 5.4)]. All
the detected malignancy cases in the anti-TIF1-Ab-positive cohort occurred between 3 years prior to and 2.5 years after
DM onset. No cancer cases were detected within the following 7.5 years in this group, whereas cancers were detected
during this period in the anti-TIF1-Ab-negative cases. Ovarian cancer was more common in the anti-TIF1-Ab-positive vs -
negative cohort: 19% vs 2%, respectively (P< 0.05). No anti-TIF1-Ab-positive case <39 years of age developed cancer,
compared with 21 (53%) of those 539 years of age.
Conclusion. Anti-TIF1-Ab-positive-associated malignancy occurs exclusively within the 3 year period on either side of
DM onset, the risk being highest in those539 years of age. Cancer types differ according to anti-TIF1-Ab status, and this
may warrant specific cancer screening approaches.
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Rheumatology key messages
. Anti-TIF1-Ab-positive dermatomyositis is associated with an increased risk of malignancy, particularly ovarian
cancer.
. This increased risk is only present in the 3 years on either side of dermatomyositis onset.
. This significant association only exists for those 539 years of age.
Introduction
The idiopathic inflammatory myopathies (IIMs) are a
group of diseases characterized by skeletal muscle
inflammation, usually symmetrical proximal muscle
weakness, elevated skeletal muscle enzymes and the
presence of circulating myositis-specific/associated
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autoantibodies (MSA/MAAs) [1, 2]. A strong association
with cancer development has been noted in the IIMs, es-
pecially in DM [3, 4]. A meta-analysis reported that the risk
of cancer development in DM is around five times higher
than that in the general population. The DM cancer risk is
twice that compared with the cancer risk in polymyositis,
and it is well recognized that cancer risk is highest in the
years prior to and following IIM onset [3].
The presence of anti-transcriptional intermediary factor
1 antibody (anti-TIF1-Ab) is DM specific and confers an
even greater risk of cancer development, with the risk of
cancer-associated myositis (CAM; cancer occurring
within 3 years prior to or following an IIM onset) ranging
from 38 to 71% [59]. It remains unclear whether the
cancer site distribution differs according to anti-TIF1-Ab
status.
Anti-TIF1-Ab is one of the most common antibodies to
be detected in juvenile DM, yet here it is not associated
with malignancy [10]. Fujimoto et al. [10] indicated a po-
tential age cut-off for cancer development in adults with
DM, whereby anti-TIF1-Ab positivity appears to confer no
cancer risk for those DM patients <40 years of age.
Further confirmation of this observation would help to
inform clinical cancer screening. Prior studies have only
followed study participants up to a maximum of 3 years
following IIM onset, due in part to the arbitrary definition of
CAM. Therefore the long-term risk of cancer associated
with anti-TIF1-Ab positivity remains unclear.
In 2007, using data from the UK Myositis Network
(UKMyoNet), Chinoy et al. [6] investigated the prevalence
of anti-TIF1-Ab in IIM cases with and without cancer and
reported that 50% of anti-TIF1-Ab-positive cases suffered
from CAM. This same cohort has now been followed up
for a further 10 years and additional anti-TIF1-Ab-posi-
tive/-negative participants have been recruited. Further
knowledge of the longer-term risk of cancer, common
sites of malignancy and age association would usefully
inform cancer screening strategies and optimize patient
management. The current study aimed to compare the
10 year cancer risk of anti-TIF1-Ab-positive vs -negative
DM cases using UKMyoNet data.
Methods
As anti-TIF1-Ab is DM specific, only DM cases were ana-
lysed. Adult DM participants (518 years of age at DM
diagnosis) were recruited from 74 participating centres
across the UK (listed in the Acknowledgements). All had
confirmed probable or definite DM according to the
Bohan and Peter criteria [11, 12]. The International
Myositis Classification Criteria [13] score was also calcu-
lated for each case and only those with a score of at least
55% (‘probable IIM’) were included. A standardized, sin-
gle-page clinical pro forma was used to collect baseline
data regarding demographics and clinical features. Date
of DM onset was defined as the time of symptom onset,
according to the recruiting consultant.
All patients were tested for the presence of MSA/MAAs.
Two 10 ml whole blood samples were taken into EDTA to
enable separation of plasma by centrifugation, permitting
autoantibody testing for determination of the presence
of MSA anti-synthetases (anti-Jo-1, -PL7, -PL12, -EJ,
-OJ, -KS, -Zo), other MSAs (anti-TIF1, -Mi-2, -SAE,
-SRP, -MDA5, -NXP2, -HMGCR) and MAA (anti-PM-Scl,
-Ku, -U1-RNP, -U3-RNP). All autoantibodies were de-
tected using radio-immunoprecipitation, except anti-
HMGCR, which was detected by ELISA.
Patients’ written consent to participate was obtained
according to the Declaration of Helsinki, ethical approval
having been gained locally at each participating centre
(North West Research Multicentre Research Ethics
Committee 98/8/86). Consent included permission to
allow individual patient details to be registered with the
UK Health and Social Care Information Centre (HSCIC)
and from which future cancer diagnosis information
could be obtained. UKMyoNet recruitment began in
1999 and cancer occurrence linkage was carried out
until December 2017.
Analysis
Baseline clinical variables of the anti-TIF1-Ab-positive
and -negative cohorts were compared. Categorical vari-
ables were compared through chi-squared testing and
non-normally distributed continuous variables through
MannWhitney U testing.
Where a cancer diagnosis was made, the time between
DM onset and cancer diagnosis was calculated and em-
ployed as the follow-up time. Where no cancer diagnosis
was made, the time between DM onset and the follow-up
cut-off date (December 2017) was calculated. Cases were
censored at the end of their follow-up period if no cancer
diagnosis was made. The proportion of each cohort that
had developed a cancer within the 3 years preceding DM
onset was calculated. Subsequently, using this proportion
as a baseline, the cumulative incidence of cancer occur-
rence after DM onset was estimated according to
KaplanMeier methods. Hazard ratios (HRs) for the time
to cancer diagnosis were calculated using a Cox propor-
tional hazard model adjusted for age, gender and smoking
status and then according to anti-TIF1-Ab status.
Results
Cohort characteristics
Data from 263 (69% female) verified DM cases with a total
of 3252 person-years follow-up were analysed (Table 1).
The median follow-up time was 10 years [interquartile
range (IQR) 615] for anti-TIF1-Ab-positive cases and
12 years (IQR 818) for anti-TIF1-Ab-negative cases.
Fifty-five (21%) of the studied cases were anti-TIF1-Ab-
positive. Of the 208 anti-TIF1-Ab-negative cases, 40
(19%) were Jo-1 positive, 15 (7%) were positive for Mi2
and 8 (4%) were positive for NXP2. A higher proportion of
the anti-TIF1-Ab-positive cases were female compared
with anti-TIF1-Ab-negative cases. Equal proportions of
each cohort smoked. The age of DM onset was signifi-
cantly older for those that subsequently developed cancer
compared with those that did not (P< 0.05). The median
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age of DM onset and cancer onset were similar in the anti-
TIF1-Ab-positive and -negative cohorts.
Cancer diagnoses during follow-up
Fifty-three (20%) of the overall cohort were diagnosed with
cancer during the entire follow-up period. An increased
proportion of anti-TIF1-Ab-positive cases developed
cancer throughout the study period compared with anti-
TIF1-Ab-negative cases [21 (38%) vs 32 (15%)] (Fig. 1).
The median time from DM onset to subsequent cancer
diagnosis throughout the entire follow-up period was
shorter for anti-TIF1-Ab-positive compared with anti-TIF1-
Ab-negative cases [1.4 years (IQR 0.72.5) vs 5.0
(2.510.4)]. All detected cancers in the anti-TIF1-Ab-posi-
tive cases occurred within 2.5 years following DM onset; no
further cases of cancer were detected within the remaining
follow-up period. In contrast, new cases of cancer were
detected in anti-TIF1-Ab-negative cases throughout the
310 year period following DM onset, with 9.8% (95% CI
7.5, 12.0) at 5 years, 11.7% (95% CI 9.2, 14.2) at 7.5 years
and 14.1% (95% CI 11.2, 16.8) at 10 years.
Cox proportional hazard modelling, adjusted for age,
gender and smoking status, revealed that anti-TIF1-Ab
positivity was significantly associated with a shorter time
between DM and cancer onset (during the entire follow-up
period) [HR 3.2 (95% CI 1.8, 5.5)].
Malignancy was more frequent in older compared with
younger anti-TIF1-Ab-positive cases. Fifteen anti-TIF1-
Ab-positive cases were <39 years of age at DM onset
and none developed cancer during the follow-up period,
whereas 21 (53%) of the 40 anti-TIF1-Ab-positive cases
539 years of age at DM onset developed cancer during
the follow-up period. Older age was significantly asso-
ciated with cancer onset [HR 1.04 (95% CI 1.02, 1.07)];
the significant association between anti-TIF1-Ab positivity
and early cancer onset only existed for those539 years of
age [HR 4.1 (95% CI 2.5, 6.7) vs HR 0.8 (95% CI 0.1, 6.5)
for patients 539 and <39 years of age, respectively].
Site of cancer
Within the anti-TIF1-Ab-positive cohort, breast cancer
was the most common malignancy (33%), followed by
ovarian cancer (19%) and lymphoma (14%). Breast
TABLE 1 Baseline demographics and time to cancer occurrence for the anti-TIF1-Ab-positive and negative cohorts
Total cohort
(n=263)
Anti-TIF1-Ab positive
(n=55)
Anti-TIF1-Ab negative
(n=208)
Female, n (%) 181 (69) 44 (80) 137 (66)*
Smokers, n (%) 82 (31) 17 (31) 65 (31)
Follow-up, years, median (IQR) 10 (717) 10 (615) 12 (818)
Age of DM onset, years, median
(IQR)
No subsequent
cancer diagnosis
47 (3560) 45 (3458) 47 (3759)
Subsequent
cancer diagnosis
59 (4866) 59 (5065) 58 (4969)
Age at cancer diagnosis, years,
median (IQR)
61 (5268) 60 (5267) 62 (5270)
Time from DM to cancer onset,
years, median (IQR)
4.3 (1.59.4) 1.4 (0.72.5) 5.0 (2.510.4)*
Cancer cases during total
follow-up period, n (%)
53 (20) 21 (38) 32 (15)*
Cases classified as CAMa, n (%) 42 (16) 21 (38) 21 (10)*
Patients with cancer within
3 years preceding DM onset,
n (%)
16 (6) 7 (13) 9 (4)*
Patients with cancer within 3years
following DM onset, n (%)
26 (10) 14 (26) 12 (6)*
aCAM: cancer occurring within 3 years either side of DM onset. Variables of the anti-TIF1-Ab-positive cohort were compared
against those of the anti-TIF1-Ab-negative cohort. *P< 0.01 (categorical variables were compared with the chi-squared test, con-
tinuous variables were compared using the MannWhitney U test). Anti-TIF1-Ab: anti-transcriptional intermediary factor 1 antibody.
FIG. 1 Kaplan-Meier plot of cumulative incidence of
cancer onset following dermatomyositis diagnosis strati-
fied according to anti-TIF1-Ab status
Anti-TIF1-Ab: anti-transcriptional intermediary factor 1
antibody.
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cancer (25%), lymphoma (13%) and bowel cancer (13%)
were the three most common cancers in the anti-TIF1-Ab-
negative cohort. Ovarian cancer constituted a significantly
higher proportion of cancers in the anti-TIF1-Ab-positive
vs -negative cases: 19% vs 2%, respectively (chi-squared
P-values <0.05). Five of the 53 (9%) cancers in the whole
cohort were ovarian and 4 (80%) of these occurred in anti-
TIF1-Ab-positive cases. Four of the 16 (25%) documented
cancers in the anti-TIF1-Ab-positive female cohort were
ovarian, compared with 1 of 26 cancers (4%) in the female
anti-TIF1-Ab-negative cohort.
Discussion
This is the first study to investigate the temporal relation-
ship between anti-TIF1-Ab positivity and cancer onset in a
large DM cohort over a 10 year follow-up period after
DM onset. Anti-TIF1-Ab-positive-associated malignancy
occurred exclusively within 3 years either side of the DM
onset, and no incident cancer cases were detected in this
group within the subsequent 7.5 years. This finding is not
likely to be due to a disparity in follow-up time between
anti-TIF1-Ab-positive and -negative cases, as the median
follow-up times were similar for both groups: 10 years and
12 years, respectively. Further, this finding is unlikely to be
due to differences in cancer detection methods, as both
cohorts’ cancer diagnoses were identified through HSCIC
data, ensuring capture of all incident cancers during the
follow-up period. Although a number of studies have now
confirmed the strong association between anti-TIF1-Ab
positivity and increased malignancy risk within 3 years of
IIM onset [58], no previous study has investigated the
longer-term risks.
We have also shown that the distribution of cancer sites
appears to vary according to anti-TIF1-Ab status, with
female anti-TIF1-Ab-positive patients at increased risk of
ovarian cancer [14, 15]. A number of studies have high-
lighted the increased risk of ovarian cancer associated
with DM, and the current study has confirmed this finding
over a 10 year longitudinal follow-up. However, this is the
first large study to identify that ovarian cancer is
overrepresented in anti-TIF1-Ab-positive individuals, sug-
gesting that the true association between DM and ovarian
cancer may be through possession of anti-TIF1-Abs.
Clinicians should therefore apply increased vigilance for
potential ovarian pathology in anti-TIF1-Ab-positive
cases.
This study has identified that the significant association
between anti-TIF1-Ab positivity and early cancer diagno-
sis exists only for those 539 years of age. This finding is
consistent with the finding by Fujimoto et al. [10], who
found that anti-TIF1-Ab-positive adults <40 years of age
did not suffer from co-existing malignancy, whereas those
>40 years of age had a high risk of cancer (75%). Our
findings add strength to the hypothesis that there exists
a subset of young adult anti-TIF1-Ab-positive cases who
do not have a discernible increased risk of cancer, similar
to that observed in TIF1-Ab-positive juvenile DM [16].
Given that older age of IIM onset is associated with
CAM regardless of autoantibody positivity [15], and anti-
TIF1-Ab positivity confers an increased risk, detailed
screening for cancer in anti-TIF1-Ab-positive patients
539 years of age is advocated.
The strengths of this study include the large anti-TIF1-
Ab-positive and -negative cohorts and the long-term de-
tection of cancers through the HSCIC. Survival bias is a
limitation, as patients would have to have survived suffi-
ciently long to be recruited into UKMyoNet. Potential in-
accuracy of identification of DM onset may have led to
under- or overestimation of the cumulative incidence of
cancer; however, this is unlikely to have impacted the
substantial difference in cancer incidence between
the anti-TIF1-Ab-positive and -negative cohorts. Further,
the lack of data on titres of anti-TIF1-Ab and lack of serial
samples have limited the ability to investigate the utility of
repeat sampling. Finally, variation in sampling times
throughout each patient’s disease stage and treatment
course could potentially have impacted upon positivity
for anti-TIF1-Ab.
A distinct approach to cancer screening according to
anti-TIF1-Ab status can be advocated. It may be that a
focus on screening for cancer within the first 3 years after
DM onset and particularly screening for ovarian cancer in
anti-TIF1-Ab-positive female patients may be required.
Our findings also strengthen the hypothesis that inflam-
matory myopathies represent a paraneoplastic reaction
initiated by attempted immune-mediated clearance of a
cancer [17].
Conclusions
This study has characterized the long-term relationship
between anti-TIF1-Ab status and cancer onset. Testing
for anti-TIF1-Ab in newly diagnosed DM cases can help
guide cancer screening strategy. The findings that earlier
cancer onset is associated with anti-TIF1-Ab positivity,
particularly in those539 years of age, and that more can-
cers are ovarian are of important clinical significance.
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Asymetric red-blue hypertrophic hand and
tenosynovitis due to acrodermatitis chronica
atrophicans
A 63-year-old woman was evaluated for the change in
appearance of her right hand beginning 6 months ago
(Fig. 1). A diagnosis of cutaneous lupus erythematosus
was suspected. Hydroxychloroquine (400 mg/day) had
no efficacy. Clinical examination showed inflammatory
joint pain, hypertrophy of the right hand with skin atrophy,
red-blue discoloration and tenosynovitis suggestive of
acrodermatitis chronica atrophicans. Western blotting re-
sults were positive for Lyme borreliosis (IgG> 240 UA/ml).
PCR in skin biopsy identified Borrelia afzelii. Treatment
with doxycycline (200 mg/day for 28 days) induced a com-
plete remission of joints symptoms and a partial remission
of skin appearance. Enlargement of the extremity with
tenosynovitis is a rare but possible manifestation of acro-
dermatitis chronica atrophicans [1, 2].
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FIG. 1 Hypertrophy of the right hand with skin atrophy,
red-blue discoloration and tenosynovitis
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